New Stock News | Yino Pharma submits application to Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on January 14th, Immvira Bioscience Inc. (referred to as Yino Weiyiyao) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Citigroup and CICC as its joint sponsors. It is reported that Yino Weiyiyao had submitted a listing application to the Hong Kong Stock Exchange main board on June 25, 2025. According to the prospectus, Yino Weiyiyao is a clinical demand-oriented biotechnology company dedicated to the discovery, development, production, and commercialization of novel oncolytic immunotherapy and engineered exosome therapy. The company has established a product pipeline, including two oncolytic immunotherapy products for solid tumors, and five engineered exosome products with clinical application prospects or direct commercialization potential. The company's core product, MVR-T3011, is a phase II novel oncolytic immunotherapy product targeting herpes simplex virus type 1 (HSV-1), combining potent tumor lytic activity with expression of anti-PD-1 antibody and IL-12.